202 related articles for article (PubMed ID: 29209323)
1. Non-Neutralizing Antibodies Directed against HIV and Their Functions.
Mayr LM; Su B; Moog C
Front Immunol; 2017; 8():1590. PubMed ID: 29209323
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity.
Bernard NF; Kiani Z; Tremblay-McLean A; Kant SA; Leeks CE; Dupuy FP
Front Immunol; 2017; 8():1033. PubMed ID: 28883824
[TBL] [Abstract][Full Text] [Related]
3. Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.
Yang K; Lan J; Shepherd N; Hu N; Xing Y; Byrd D; Amet T; Jewell C; Gupta S; Kounga C; Gao J; Yu Q
J Virol; 2015 Sep; 89(18):9393-406. PubMed ID: 26136568
[TBL] [Abstract][Full Text] [Related]
4. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.
DiLillo DJ; Palese P; Wilson PC; Ravetch JV
J Clin Invest; 2016 Feb; 126(2):605-10. PubMed ID: 26731473
[TBL] [Abstract][Full Text] [Related]
5. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
[TBL] [Abstract][Full Text] [Related]
6. Which Antibody Functions are Important for an HIV Vaccine?
Su B; Moog C
Front Immunol; 2014; 5():289. PubMed ID: 24995008
[TBL] [Abstract][Full Text] [Related]
7. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
[TBL] [Abstract][Full Text] [Related]
8. Fc receptors and the diversity of antibody responses to HIV infection and vaccination.
Lin LY; Carapito R; Su B; Moog C
Genes Immun; 2022 Aug; 23(5):149-156. PubMed ID: 35688931
[TBL] [Abstract][Full Text] [Related]
9. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies.
Holl V; Peressin M; Moog C
Viruses; 2009 Dec; 1(3):1265-94. PubMed ID: 21994593
[TBL] [Abstract][Full Text] [Related]
11. Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.
Boesch AW; Alter G; Ackerman ME
Curr Opin HIV AIDS; 2015 May; 10(3):160-9. PubMed ID: 25700208
[TBL] [Abstract][Full Text] [Related]
12. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
Vogel T; Kurth R; Norley S
J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
[TBL] [Abstract][Full Text] [Related]
13. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
14. [Anti-HIV antibodies: multiple antiviral activities].
Peressin M; Holl V; Moog C
Med Sci (Paris); 2014 Jan; 30(1):69-75. PubMed ID: 24472462
[TBL] [Abstract][Full Text] [Related]
15. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.
Hessell AJ; McBurney S; Pandey S; Sutton W; Liu L; Li L; Totrov M; Zolla-Pazner S; Haigwood NL; Gorny MK
Vaccine; 2016 May; 34(24):2713-21. PubMed ID: 27102818
[TBL] [Abstract][Full Text] [Related]
16. On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development?
Parsons MS; Muller S; Kohler H; Grant MD; Bernard NF
Hum Vaccin Immunother; 2013 Jul; 9(7):1532-8. PubMed ID: 23571168
[TBL] [Abstract][Full Text] [Related]
17. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
18. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunity to HIV-1: neutralization and beyond.
Huber M; Trkola A
J Intern Med; 2007 Jul; 262(1):5-25. PubMed ID: 17598812
[TBL] [Abstract][Full Text] [Related]
20. Evolution of the Humoral Response during HCV Infection: Theories on the Origin of Broadly Neutralizing Antibodies and Implications for Vaccine Design.
Murira A; Lapierre P; Lamarre A
Adv Immunol; 2016; 129():55-107. PubMed ID: 26791858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
